The biopharmaceutical company lifted its earnings forecast to $6.75-$7 a share and revenue guidance to $49 billion-$50 billion from prior ranges of $6.05-$6.35 and $46 billion-$47.5 billion.
verifying reliability
No specialized terms available for this topic.